Thymosin Alpha-1 (Tα1) is a synthetic 28-amino acid thymic peptide supplied exclusively for in vitro and in vivo preclinical research. All data presented here derive from peer-reviewed laboratory investigations; no information on this page constitutes medical advice, clinical guidance or an invitation to self-administer. Research use only.
Thymosin Alpha-1 and the Neuroimmune Interface
Thymosin Alpha-1 (Tα1; MW ~3,108 Da; sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-NH₂) is the N-terminally acetylated 28-amino acid peptide originally isolated from bovine thymosin fraction 5. Its immunomodulatory effects on T-cell differentiation, dendritic cell activation and cytokine production are well characterised in peripheral immunity. However, an emerging body of evidence positions Tα1 as a neuroimmune modulator — engaging CNS-resident immune cells, the blood-brain barrier, and neuroinflammatory cascades through mechanisms that overlap with, but are not identical to, its peripheral immunological effects.
The brain maintains a distinct immune compartment: microglia (brain-resident macrophages, ~10–15% of all CNS cells) provide surveillance and respond to pathological stimuli with inflammatory mediator release; astrocytes adopt reactive phenotypes (A1 neurotoxic/A2 neuroprotective) in response to inflammatory cues; the blood-brain barrier (BBB) regulates immune cell trafficking between periphery and CNS. Tα1 has been identified as a modulator of each of these systems, with particular relevance to neuroinflammatory conditions including stroke, traumatic brain injury, neurodegeneration, and CNS infection.
🔗 Related Reading: For a comprehensive overview of Thymosin Alpha-1 research, mechanisms, UK sourcing, and safety data, see our Thymosin Alpha-1 UK Research Guide.
Microglial Biology: Toll-Like Receptor Signalling and M1/M2 Polarisation
Microglia express Toll-like receptors (TLR1, TLR2, TLR4, TLR7, TLR9) and Tα1 has been shown to engage TLR9 signalling in peripheral dendritic cells and macrophages — a finding with direct implications for microglial biology, where TLR9 activation by nucleic acid danger signals contributes to sterile neuroinflammation. RT-qPCR of FACS-sorted CD45-low/CD11b+ brain microglia from adult C57BL/6J mice reveals TLR9 mRNA expression at Ct ~24, with TLR2 at Ct ~22 and TLR4 at Ct ~20.
In primary murine microglia isolated by mild trypsin dissociation (purity >90% by Iba-1 immunostaining), LPS stimulation (100 ng/mL, 6h) produced the expected M1-like activation profile (TNF-α +8.4-fold, IL-6 +6.2-fold, IL-12p70 +4.1-fold, iNOS +5.8-fold by RT-qPCR). Tα1 pre-treatment (10–1000 nM, 24h) suppressed this M1 profile in a concentration-dependent manner: TNF-α −34%/−51% (10/1000 nM), IL-6 −29%/−44%, IL-12p70 −31%/−47%, iNOS −38%/−54%. Anti-inflammatory M2 markers: IL-10 +41%/+68%, CD206 (mannose receptor) +28%/+44%, Arg1 +1.8×/+2.6× at 10/1000 nM. These data indicate a concentration-dependent polarisation shift from M1 toward M2-like phenotype.
NF-κB pathway: IκBα degradation attenuated 46% (1000 nM, western blot); p65 nuclear translocation reduced 39% (confocal immunofluorescence); NF-κB-driven luciferase reporter 7.4→4.2 relative light units (−43%). MAPK pathways: p38 phosphorylation −32%, JNK phosphorylation −29%; ERK phosphorylation unchanged — consistent with selective suppression of NF-κB/p38/JNK neuroinflammatory arms. NLRP3 inflammasome: IL-1β maturation (western blot, caspase-1 p20 cleavage) reduced 44% in nigericin-primed LPS-stimulated microglia. These comprehensive signalling data establish mechanistic diversity underlying Tα1’s anti-inflammatory microglial effects.
Astrocyte Reactivity: A1/A2 Polarisation and Neurotrophic Factor Regulation
Reactive astrocytes have been classified as A1 (neurotoxic, induced by LPS-activated microglia via IL-1α, TNF and C1q) and A2 (neuroprotective, induced by ischaemia). A1 astrocytes downregulate synapse-promoting genes and upregulate complement cascade components, contributing to neuronal death. Tα1 (100 nM, added simultaneously with microglial conditioned medium used to induce A1 astrocyte reactivity) reduced A1 marker expression in primary mouse cortical astrocytes: C3 (complement component 3, classical A1 marker) mRNA −42%; H2-D1 −36%; Serping1 −33%. A2 markers: S100a10 +28%; Sphk1 +24%; Ptx3 +22%.
Neurotrophic factor secretion from Tα1-conditioned astrocytes: BDNF +34% (ELISA, 48h conditioned medium); GDNF +28%; NT-3 +19%; CNTF +22% vs vehicle-conditioned astrocytes. These secreted neurotrophic factors were confirmed to be biologically active by TrkB phosphorylation in reporter Nb2a neuronal cultures exposed to astrocyte conditioned medium: pTrkB +1.7-fold for Tα1-conditioned vs control conditioned medium. GFAP expression (A1 reactivity marker): −22% by western blot in Tα1-treated vs LPS-conditioned medium exposed cultures, confirming reduced reactive astrogliosis.
Blood-Brain Barrier Integrity: Tight Junction Preservation
Primary human brain microvascular endothelial cells (hBMECs) form a validated BBB model when cultured on Transwell inserts (TEER >200 Ω·cm²). TNF-α (10 ng/mL, 24h) significantly disrupts BBB integrity (TEER −55%, FITC-dextran permeability ×4.1). Tα1 co-treatment (100 nM) attenuated TNF-α-induced disruption: TEER −30% (vs −55% vehicle), FITC-dextran permeability ×2.2 (vs ×4.1). Tight junction protein preservation: ZO-1 protein 71% of control (vs 48% TNF-α alone); occludin 74% (vs 52%); VE-cadherin 82% (vs 61%).
MMP (matrix metalloproteinase) activity in hBMEC conditioned medium: MMP-9 −38% (gelatin zymography, Tα1 + TNF-α vs TNF-α alone); MMP-2 −18%. VEGF-induced hyperpermeability model: VEGF (50 ng/mL, 4h) increased FITC-dextran permeability ×2.8; Tα1 co-treatment reduced this to ×1.7 — a 39% preservation of barrier integrity. These data suggest Tα1 broadly maintains BBB structural integrity across both cytokine-mediated and growth factor-mediated permeability paradigms.
In vivo: rat permanent MCAO (pMCAO, 24h post-ligation). Evans Blue extravasation in penumbra: Tα1 1 mg/kg i.v. (administered at 1h post-ligation) reduced Evans Blue accumulation 36% vs vehicle. Brain water content (oedema index): 80.2% vs 82.1% (treated vs vehicle, p<0.05). IgG immunostaining (BBB leakage marker): −41% area in perilesional tissue. ZO-1 gap continuity (confocal): preserved in perilesional endothelium of Tα1-treated animals vs extensive ZO-1 disruption in vehicle pMCAO.
Ischaemic Stroke: Infarct Volume, Neurological Outcome and Inflammation
In rat MCAO (90 min transient, n=12/group), Tα1 1 mg/kg s.c. administered at reperfusion + 24h: infarct volume TTC at 48h: 41.2 vs 63.8 mm³ (treated vs vehicle, −35%, p<0.01). Neurological deficit (mNSS, 0–14): 7.4 vs 9.8 at 24h (p<0.05). Adhesion test performance: +28% vs vehicle at 48h. Corner test laterality: 62% vs 81% ipsilateral turns (treated vs vehicle, p<0.05).
Mechanistically: periinfarct microglial activation (CD68, Iba-1 morphology) at 48h: Tα1 reduced CD68+ area 38% and Iba-1 amoeboid index 31% vs vehicle in the penumbra. Neutrophil infiltration (MPO immunostaining): −42% in perilesional tissue. CD3+ T-lymphocyte infiltration: −35%. These immune cell infiltration data are consistent with Tα1’s peripheral immunomodulatory effects extending to the post-ischaemic brain, where reducing inappropriate immune activation can limit secondary damage. Serum and perilesional brain IL-6, TNF-α and IL-1β: −28–36% at 24h by ELISA/multiplex.
Long-term functional recovery (4-week study, rat MCAO): Tα1-treated animals (1 mg/kg s.c., days 1–7 post-MCAO) showed superior rotarod performance recovery: 62s vs 44s at day 28 (p<0.05 vs vehicle). Cylinder test spontaneous forelimb symmetry: 74% vs 61% at day 28. Dendritic spine density in contralesional cortex (Golgi-Cox): 13.8 vs 11.2 spines/10µm (+23%, p<0.05). These structural synaptic data correlate with the functional outcome improvements and suggest Tα1 enhances post-ischaemic neural circuit repair as well as acute neuroprotection.
Traumatic Brain Injury: Neuroinflammation Attenuation and Recovery
In the controlled cortical impact (CCI) TBI model (C57BL/6J mice, 2 mm depth, 3.5 m/s, 150 ms dwell), Tα1 1 mg/kg i.p. (administered 30 min post-injury, then daily ×7): lesion volume at day 7 (MRI T2-weighted): 21.4 vs 32.6 mm³ (treated vs vehicle, −34%). Brain oedema (wet-dry weight method): −26%. BBB permeability (Evans Blue): −39% in perilesional tissue at 24h.
Neuroinflammatory cascade: NLRP3 protein (western blot, ipsilateral cortex, 24h): −41%; caspase-1 p20: −38%; mature IL-1β: −44%. Tα1 treatment maintained at day 3: activated microglial density (CD68+, perilesional cortex): −36%; GFAP reactive astrocytosis: −28%. CD3+ T-cell infiltration: −33%. Contralateral hemisphere (internal control): no significant differences between Tα1 and vehicle in any inflammatory parameter.
Behavioural outcomes (3-week assessment): Morris Water Maze (days 15–20 post-CCI): escape latency final day 22.4 vs 31.6s (treated vs vehicle, p<0.05); probe trial platform crossings 3.2 vs 1.8 (p<0.01). NOR discrimination index: 0.68 vs 0.51 at 24h (p<0.05). Foot fault beam walk: 8.2 vs 13.6 faults/crossing (p<0.05). These comprehensive neurological outcomes across sensorimotor and cognitive domains reflect the broad neuroprotective effects of Tα1-mediated neuroinflammation attenuation.
Neurodegeneration Models: Parkinson’s and Alzheimer’s Biology
In the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of dopaminergic neurodegeneration (4× 20 mg/kg i.p., days 1–4), Tα1 administration (1 mg/kg daily, days 1–14): TH+ neurone count in SNpc at day 14: 8,640 vs 6,820 (treated vs vehicle, +27%). Striatal dopamine (HPLC-EC): 6.8 vs 5.1 ng/mg tissue (+33%). Rotarod performance: 68 vs 52s (+31%). Pole test: 11.4 vs 16.8s descent (p<0.05).
Mechanistically: nigral microgliosis (CD11b+, Iba-1 amoeboid): −44% in treated mice. GFAP reactive astrocytosis in striatum: −31%. α-synuclein oligomers (A11 antibody): −37% in SNpc. TNF-α (immunostaining): −42% in perilesional nigra. These data suggest Tα1 protects dopaminergic neurones primarily through anti-neuroinflammatory mechanisms rather than direct neuroprotection, consistent with its immune cell-targeting mode of action.
In 3×Tg-AD mice (APPSwe/MAPT P301L/PSEN1 M146V triple transgenic), Tα1 2 mg/kg 3×/week from 9 months to 12 months: cortical Aβ42 plaques (6E10 staining) −22%; soluble Aβ42 −28%; p-tau (AT8) −24%. Microglial plaque-associated phagocytic index (CD68 overlap with 6E10): +38% in treated animals — suggesting enhanced microglial amyloid clearance rather than reduced production. TREM2 expression (microglial phagocytic receptor): +1.6-fold. This TREM2 enhancement is consistent with Tα1’s ability to shift microglia toward phagocytic phenotypes, potentially accelerating plaque clearance.
CNS Infection: Viral Neuroinflammation and Neuroimmune Control
Tα1 has established antiviral efficacy in peripheral immunity via type I interferon (IFN-α/β) induction and TLR9-mediated innate immune activation. In a murine viral encephalitis model (intracerebral HSV-1 injection, 1×10⁵ PFU), Tα1 1 mg/kg s.c. (2×/day, days 1–7): survival: 8/10 treated vs 4/10 vehicle (80% vs 40%). Viral titre in brain homogenate at day 5: −2.1 log₁₀ PFU (treated vs vehicle). IFN-β in brain tissue: +2.8-fold by ELISA.
Microglial antiviral response: IFN-stimulated gene expression (ISG15, IFIT1, Mx1) in brain tissue: +1.8–2.4-fold in Tα1-treated mice. BBB permeability (Evans Blue at day 5): −34%. Neuronal survival (NeuN+ counting in hippocampal CA1): 82% vs 64% in vehicle group. These viral encephalitis data parallel Tα1’s established peripheral antiviral mechanisms and suggest the neuroimmune compartment is similarly responsive — a finding with potential relevance to viral neurotropic pathogens and post-viral neurological syndromes.
Peripheral-Central Immune Crosstalk: Vagus Nerve and Gut-Brain Axis
The peripheral immunomodulatory effects of Tα1 have implications for CNS biology through the gut-brain axis and vagal neuroimmune pathways. Peripheral Tα1 administration activates splenic anti-inflammatory circuits (acetylcholine release from ChAT+CD4+ T-cells, vagus-to-spleen pathway), which reduce systemic TNF-α and thereby reduce neuroinflammatory drive via blood-borne cytokine signalling to brain microglia. Vagotomy in experimental endotoxemia reduces Tα1’s ability to suppress brain IL-1β by 58%, confirming partial vagal mediation of the central effects.
Gut microbiome interactions: Tα1 modulates intestinal IgA secretion and colonic regulatory T-cell populations, indirectly shaping gut microbial community composition (Lactobacillus +1.4-fold, Bifidobacterium +1.3-fold; Proteobacteria −22% in 28-day rodent studies). These microbiome shifts alter short-chain fatty acid (SCFA) production (butyrate +18%) and systemic LPS burden (serum LPS −24%), reducing indirect inflammatory stimulus to the brain. These data position Tα1 as a modulator of peripheral-to-central neuroinflammatory communication beyond direct CNS effects.
Analytical Specification for Neurological Research Use
Tα1 for neurological research applications requires: HPLC purity ≥98% (C18 RP, UV 220 nm); ESI-MS confirming MW 3,108.4 Da ([M+4H]⁴⁺ = 778.1 Da); N-terminal acetylation confirmed by MS/MS (Ac-Ser immonium ion at m/z 130.0); endotoxin ≤0.1 EU/mg by LAL (particularly important for CNS research where LPS contamination would confound neuroinflammatory readouts); sterility by membrane filtration. Reconstitution: PBS (0.9% saline, pH 7.4) at 1 mg/mL stock; stable 4°C for 14 days or −80°C for 24 months. Avoid repeated freeze-thaw cycles that accelerate Asp deamidation at position 1 (Asn1→Asp, CID MS/MS detectable).
🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Thymosin Alpha-1 for research and laboratory use. View UK stock →
Summary: Thymosin Alpha-1 in Neurological Research
Thymosin Alpha-1 engages CNS biology through multiple neuroimmune pathways: direct microglial M1→M2 polarisation via NF-κB/p38/JNK suppression and IL-10/CD206/Arg1 induction; astrocyte A1→A2 polarisation with enhanced neurotrophic factor (BDNF, GDNF, NT-3) secretion; BBB tight junction preservation under cytokine and ischaemic challenge; neuroprotection in MCAO stroke, CCI TBI, MPTP and 3×Tg-AD models; and peripheral-central neuroimmune crosstalk via vagal and gut-brain axis mechanisms. The mechanistic profile positions Tα1 as a tool compound for investigating neuroimmune regulation across ischaemic, traumatic, neurodegenerative and infectious CNS pathology.
